Trial Profile

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer: a Prospective, Randomized Controlled Clinical Trial

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary) ; Surufatinib (Primary) ; Gemcitabine
Indications Adenocarcinoma; Liver metastases; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

31 Dec 2024 Planned number of patients changed from 83 to 90.
31 Dec 2024 Planned End Date changed from 1 Feb 2025 to 1 Jun 2025.
29 Apr 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Jul 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com